Peripheral artery disease and erectile dysfunction may appear to involve different parts of the body, but they often arise from the same vascular biology. Both can reflect impaired endothelial function, atherosclerosis, reduced arterial flexibility, and inadequate blood flow. For some men, difficulty achieving or maintaining an erection is therefore more than a quality-of-life issue: it may be an early reason to evaluate cardiovascular and peripheral vascular risk.
How Peripheral Artery Disease and Erectile Dysfunction Are Connected
Peripheral artery disease (PAD) occurs when atherosclerotic plaque narrows arteries outside the heart and brain, most commonly those supplying the legs. Reduced blood flow may cause calf, thigh, or buttock discomfort during walking, slow-healing foot wounds, skin-temperature differences, or diminished pulses. PAD can also be silent, particularly in people who are less active or who have diabetic neuropathy.
An erection is also a vascular event. Sexual stimulation activates nitric oxide signaling, relaxes smooth muscle in the penile arteries and erectile tissue, and permits a rapid increase in blood flow. Veins are then compressed to help maintain rigidity. Any process that limits arterial dilation or damages the endothelium can weaken this response.
The penile arteries are smaller than the coronary or major leg arteries. The “artery-size hypothesis” proposes that a similar atherosclerotic burden may become functionally apparent in smaller vessels before it produces symptoms in larger ones. This does not mean every case of erectile dysfunction (ED) is caused by atherosclerosis. Hormonal disorders, medication effects, neurologic disease, pelvic surgery, anxiety, depression, and relationship factors can all contribute. It does mean that persistent ED—especially when it develops gradually in a man with vascular risk factors—deserves a broader clinical assessment.
Recent population data reinforce the connection. Wang and Ni analyzed 2,394 US men aged 40 or older in the 2001–2004 National Health and Nutrition Examination Survey (NHANES). PAD, defined by an ankle-brachial index below 0.90 in either leg, was present in 11.4% of men with ED versus 2.6% of those without it. After adjustment for potential confounders, ED remained associated with approximately twice the odds of PAD [1]. Because this was a cross-sectional analysis, it establishes association rather than causation, but the size and consistency of the relationship are clinically relevant.
The Vascular Biology Behind Both Conditions
Healthy arteries continuously adjust their diameter. The endothelium—the cellular lining of blood vessels—produces nitric oxide, which signals vascular smooth muscle to relax. Smoking, high blood pressure, elevated LDL cholesterol, insulin resistance, diabetes, chronic inflammation, and aging can reduce nitric oxide bioavailability while increasing oxidative stress. The result is endothelial dysfunction: arteries become less responsive before they necessarily become severely obstructed.
A 2024 systematic review and meta-analysis by Peng and colleagues combined 57 studies involving 7,312 participants. Compared with men without ED, those with ED had lower flow-mediated dilation, greater carotid intima-media thickness, higher augmentation index, faster pulse-wave velocity, and fewer endothelial progenitor cells [2]. These measurements capture different aspects of endothelial health, arterial wall thickness, and stiffness. The findings support the view that ED frequently accompanies systemic vascular dysfunction rather than an isolated defect in penile tissue.
The meta-analysis did not find a significant pooled difference in ankle-brachial index between groups. That detail matters: ED should not be treated as a diagnostic test for PAD, and a normal ankle-brachial index does not explain or exclude every vascular cause of ED. Instead, erectile symptoms can be understood as one item in a larger risk profile that includes age, symptoms, blood pressure, lipid levels, glucose regulation, tobacco exposure, family history, and established cardiovascular disease.
PAD and ED can also share nonvascular contributors. Diabetes may damage autonomic and peripheral nerves as well as arteries. Certain antihypertensive drugs can affect sexual function even while blood-pressure control reduces long-term vascular risk. Limited walking due to PAD may reduce exercise capacity, worsen cardiometabolic fitness, and contribute to sexual symptoms indirectly. A careful evaluation therefore looks for overlapping mechanisms rather than assuming a single cause.
Symptoms That Should Prompt Medical Evaluation
Persistent ED is generally defined clinically by recurrent difficulty achieving or maintaining an erection sufficient for satisfactory sexual activity. A single episode during illness, fatigue, heavy alcohol use, or acute stress is common and does not establish a vascular disorder. A progressive pattern over weeks or months is more informative, particularly when spontaneous or morning erections also become less reliable.
Possible PAD symptoms include muscle aching, cramping, heaviness, or fatigue in one or both legs during walking that improves with rest. Some men notice coldness in one foot, reduced hair growth on the lower leg, shiny skin, weak pulses, numbness, or wounds that heal slowly. Advanced disease may cause foot or toe pain at rest, often worse when lying flat. Sudden limb pain, pallor, coldness, weakness, or loss of sensation is an emergency because it can indicate acute arterial obstruction.
Men with ED should seek prompt assessment for chest pressure, unexplained breathlessness, fainting, or symptoms brought on by exertion. Sexual activity imposes a cardiovascular workload, and treatment decisions should account for whether a patient is stable enough for that activity. ED medication must not be combined with nitrates such as nitroglycerin or isosorbide because the interaction can cause a dangerous fall in blood pressure.
The absence of leg pain does not rule out PAD. People who walk slowly, avoid exertion, or have neuropathy may never reach the activity level that produces classic claudication. Conversely, leg pain is often caused by arthritis, spinal stenosis, venous disease, or muscular conditions. Symptoms guide testing, but they do not replace it.
How Clinicians Screen for Vascular Disease
Evaluation usually begins with a medical and sexual history. A clinician may ask about onset, consistency, libido, morning erections, exercise tolerance, walking-related leg symptoms, medications, tobacco use, and mental health. Examination can include blood pressure, body composition, cardiac findings, leg and foot pulses, skin changes, and genital or neurologic findings when indicated.
Basic laboratory testing is individualized but may include fasting glucose or hemoglobin A1c, a lipid panel, kidney function, and morning total testosterone when symptoms suggest androgen deficiency. The goal is not simply to assign an ED medication. It is to identify modifiable conditions that affect both sexual function and long-term health.
The ankle-brachial index (ABI) compares systolic blood pressure at the ankle with pressure at the arm. A resting ABI of 0.90 or lower generally supports a PAD diagnosis, although interpretation can be complicated by calcified, noncompressible arteries, especially in diabetes or chronic kidney disease. Exercise ABI, toe-brachial measurements, duplex ultrasound, or vascular imaging may be appropriate when symptoms and resting results do not agree.
A separate 2024 NHANES analysis by Wu, Zhang, and Zheng found an L-shaped association between ankle-brachial pressure index and ED. Below an inflection point of 1.14, lower index values were associated with greater odds of ED after adjustment [3]. The study does not establish a screening threshold for sexual dysfunction, and its cross-sectional design limits causal conclusions. It does, however, add population-level evidence that lower-extremity arterial measures and erectile function track together.
Clinical risk assessment may also include an estimate of 10-year atherosclerotic cardiovascular disease risk. Referral to primary care, cardiology, or vascular medicine may be appropriate for men with concerning symptoms, abnormal pulses, a low ABI, multiple uncontrolled risk factors, or uncertain exercise safety. Urologic evaluation is useful when the diagnosis is unclear, first-line treatment is ineffective, or structural and hormonal causes are suspected.
Treatment Addresses Risk and Symptoms
Management begins with the vascular risks shared by PAD and ED. Smoking cessation is one of the highest-value interventions. Regular walking and structured exercise may improve functional capacity in PAD and may support endothelial health and erectile function. Blood-pressure treatment, lipid lowering, diabetes management, adequate sleep, weight management when appropriate, and a Mediterranean-style eating pattern can improve the biological environment in which erections occur. These measures are not immediate cures, and their effect varies, but they address disease processes that medication alone cannot reverse.
Confirmed PAD may require antiplatelet therapy, intensive lipid lowering, supervised exercise therapy, or revascularization depending on symptoms and anatomy. Those decisions belong to a clinician because bleeding risk, comorbidities, and disease severity matter. Foot care is particularly important for people with diabetes or reduced sensation.
For ED, phosphodiesterase type 5 (PDE5) inhibitors enhance the nitric oxide–cyclic GMP pathway and are first-line therapy for many eligible men. They require sexual stimulation to work and do not remove arterial plaque. Response may be less predictable when arterial inflow is substantially impaired, diabetes is poorly controlled, nerve injury is present, or dosing instructions are not followed. Dose selection and drug interactions require physician review; combining PDE5 inhibitors without specific medical supervision can increase adverse effects such as headache, flushing, dizziness, low blood pressure, and prolonged erection.
Some supportive compounds have been studied for endothelial effects, but evidence quality varies and supplement formulations are not interchangeable with prescription treatment. The presence of an ingredient with plausible vascular biology does not prove that a specific combination improves PAD or prevents cardiovascular events. Claims should remain limited to the formulation and outcomes actually studied.
Conclusion
ED and PAD often share atherosclerosis, endothelial dysfunction, and cardiometabolic risk. The association does not mean one condition automatically diagnoses the other, but new or progressive erectile symptoms can provide a useful opportunity to review vascular health. Men with walking-related leg discomfort, abnormal foot findings, diabetes, smoking history, hypertension, high cholesterol, or reduced exercise tolerance should discuss whether PAD screening is appropriate. Treating sexual symptoms and evaluating cardiovascular risk are complementary parts of the same evidence-based approach.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including Red Pill, starting with a free online assessment at questionnaire.getonyxmd.com. You can also review additional evidence-based topics in the men's health library.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Wang G, Ni C. Association of erectile dysfunction and peripheral arterial disease in NHANES 2001–2004: a cross-sectional study. Frontiers in Endocrinology. 2024;15:1439609. doi:10.3389/fendo.2024.1439609
Peng H, Zhang H, Xin S, Li H, Liu X, Wang T, Liu J, Zhang Y, Song W. Associations between erectile dysfunction and vascular parameters: a systematic review and meta-analysis. World Journal of Men's Health. 2024;42(4):712–726. doi:10.5534/wjmh.230192
Wu X, Zhang Y, Zheng X. Association between ankle-brachial blood pressure index and erectile dysfunction in US adults: a large population-based cross-sectional study. Frontiers in Endocrinology. 2024;15:1436043. doi:10.3389/fendo.2024.1436043
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.